- Home
- TTD vs EXEL Comparison
TTD vs EXEL Comparison
Compare TTD & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TTD | EXEL |
|---|---|---|
| Founded | 2009 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0B | 14.0B |
| IPO Year | 2016 | 2000 |
Fundamental Metrics
Financial Performance| Metric | TTD | EXEL |
|---|---|---|
| Price | $19.32 | $55.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 34 | 21 |
| Target Price | $46.22 | ★ $46.50 |
| AVG Volume (30 Days) | ★ 15.2M | 2.5M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.38 | ★ 57.95 |
| EPS | 0.08 | ★ 0.79 |
| Revenue | ★ $2,896,284,000.00 | $452,477,000.00 |
| Revenue This Year | $13.94 | $13.61 |
| Revenue Next Year | $12.61 | $13.13 |
| P/E Ratio | $237.06 | ★ $70.66 |
| Revenue Growth | ★ 18.47 | N/A |
| 52 Week Low | $16.98 | $33.76 |
| 52 Week High | $91.45 | $57.57 |
Technical Indicators
Market Signals| Indicator | TTD | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 49.22 | 56.26 |
| Support Level | $16.98 | $40.77 |
| Resistance Level | $24.25 | $57.57 |
| Average True Range (ATR) | 0.88 | 1.53 |
| MACD | 0.20 | -0.09 |
| Stochastic Oscillator | 65.40 | 59.48 |
Price Performance
Historical ComparisonAbout TTD The Trade Desk Inc.
The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on devices like computers, smartphones, and connected TVs. It uses data in an iterative manner to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry, and it generates revenue from fees based on a percentage of what its clients spend on advertising.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.